215 related articles for article (PubMed ID: 38302471)
61. Proteomic profiling of metabolic proteins as potential biomarkers of radioresponsiveness for colorectal cancer.
Islam Khan MZ; Tam SY; Azam Z; Law HKW
J Proteomics; 2022 Jun; 262():104600. PubMed ID: 35526805
[TBL] [Abstract][Full Text] [Related]
62. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
Cappuzzo F; Finocchiaro G; Rossi E; Jänne PA; Carnaghi C; Calandri C; Bencardino K; Ligorio C; Ciardiello F; Pressiani T; Destro A; Roncalli M; Crino L; Franklin WA; Santoro A; Varella-Garcia M
Ann Oncol; 2008 Apr; 19(4):717-23. PubMed ID: 17974556
[TBL] [Abstract][Full Text] [Related]
63. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
64. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
65. Integrated Profiling Identifies
Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
Front Immunol; 2021; 12():722807. PubMed ID: 34646265
[TBL] [Abstract][Full Text] [Related]
66. Plasma proteomic characterization of colorectal cancer patients with FOLFOX chemotherapy by integrated proteomics technology.
Wang X; Zhang K; He W; Zhang L; Gao B; Tian R; Xu R
Clin Proteomics; 2024 Apr; 21(1):27. PubMed ID: 38580967
[TBL] [Abstract][Full Text] [Related]
67. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.
Balko JM; Black EP
BMC Cancer; 2009 May; 9():145. PubMed ID: 19439077
[TBL] [Abstract][Full Text] [Related]
68. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
69. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
Komor MA; Bosch LJ; Coupé VM; Rausch C; Pham TV; Piersma SR; Mongera S; Mulder CJ; Dekker E; Kuipers EJ; van de Wiel MA; Carvalho B; Fijneman RJ; Jimenez CR; Meijer GA; de Wit M
J Pathol; 2020 Mar; 250(3):288-298. PubMed ID: 31784980
[TBL] [Abstract][Full Text] [Related]
70. Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.
Bertuzzi M; Marelli C; Bagnati R; Colombi A; Fanelli R; Saieva C; Ceroti M; Bendinelli B; Caini S; Airoldi L; Palli D
BMC Cancer; 2015 Feb; 15():56. PubMed ID: 25884309
[TBL] [Abstract][Full Text] [Related]
71. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
72. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
73. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study.
Kim JH; Cha Y; Shin SJ; Park YS; Kang JH; Kim C; Lim SH; Kang MJ; Kim JG; Hwang IG; Choi JK; Shin SH; Kang SY; Lee SC; Lim ST; Kim JS; Jeung HC; Kang MH; Choi IS; Ryu HW; Lee KH; Lee MH; Lee JY; Park JH; Jeon SY; Lee N; Park CY; Kim YH
Anticancer Res; 2024 Jan; 44(1):347-359. PubMed ID: 38160001
[TBL] [Abstract][Full Text] [Related]
74. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
75. Proteomics for early detection of colorectal cancer: recent updates.
Alnabulsi A; Murray GI
Expert Rev Proteomics; 2018 Jan; 15(1):55-63. PubMed ID: 29064727
[TBL] [Abstract][Full Text] [Related]
76. Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.
Ibrahimi AK; Al-Hussaini M; Laban DA; Ammarin R; Wehbeh L; Al-Mousa A
CNS Oncol; 2023 Jun; 12(2):CNS97. PubMed ID: 37129184
[TBL] [Abstract][Full Text] [Related]
77. Profiling of differentially expressed proteins in stage IV colorectal cancers with good and poor outcomes.
Kim HJ; Kang UB; Lee H; Jung JH; Lee ST; Yu MH; Kim H; Lee C
J Proteomics; 2012 Jun; 75(10):2983-97. PubMed ID: 22178445
[TBL] [Abstract][Full Text] [Related]
78. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
79. Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.
Kopylov AT; Stepanov AA; Malsagova KA; Soni D; Kushlinsky NE; Enikeev DV; Potoldykova NV; Lisitsa AV; Kaysheva AL
Molecules; 2020 Jan; 25(3):. PubMed ID: 32023884
[No Abstract] [Full Text] [Related]
80. Encorafenib, binimetinib and cetuximab combined therapy for patients with
Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
